Health-related quality of life in early psoriatic arthritis compared with
early rheumatoid arthritis and a general population
Mats Geijer
a,b,c, Gerd-Marie Alenius
d,*
, Lars Andre
e, Tomas Husmark
f, Per T Larsson
g,
Ulla Lindqvist
h, Ingrid Thyberg
i, Elke Theander
ja
Department of Radiology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
bRegion V€astra G€otaland, Sahlgrenska University Hospital, Department of Radiology, Gothenburg, Sweden cDepartment of Clinical Sciences, Lund University, Lund, Sweden
dPublic Health and Clinical Medicine/Rheumatology, Umea
University, Umea
SE-901 85, Sweden
eHelsinborgs lasarett, Helsingborg, Sweden f
Department of Rheumatology, Falu Hospital, Falun, Sweden
g
Department of Rheumatology, Karolinska University Hospital Huddinge, Stockholm, Sweden
h
Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden
iDepartment of Rheumatology, Department of and Clinical and Experimental Medicine, Link€oping University, Link€oping, Sweden jDepartment of Rheumatology, Skane University Hospital and Lund University, Malm€o, Sweden
A B S T R A C T
Objective: Both psoriatic arthritis (PsA) and rheumatoid arthritis (RA) have a significant impact on quality of
life, but few reports have compared the two diseases. The current study assessed health-related quality of
life (HRQoL) in PsA at diagnosis and afterfive years compared with early rheumatoid arthritis (RA) and a
matched general population.
Methods: Patients with early PsA and early RA included in two Swedish registries with HRQoL data measured
by the Medical Outcomes Study Short Form 36 (SF-36) at baseline and atfive years follow-up were included.
Differences in SF-36 scores compared with the general population were calculated for each patient. Physical function, disease activity, the delay before diagnosis, pain, and general wellbeing were used as explanatory variables. Statistical tests included t-tests and univariate and multivariate linear regression.
Results: PsA (n = 166) and RA (n = 133) patients of both sexes had significantly reduced HRQoL at disease
onset. Afterfive years, PsA patients still had impairments in several domains of SF-36, whereas RA patients
had an almost normalized HRQoL. The time from symptom onset to diagnosis, disease activity, and disability independently contributed to the reduced improvement in PsA.
Conclusion: Both early PsA and RA are characterized by severely reduced HRQoL. Despite more severe disease at inclusion, normalization of HRQoL is seen in patients with RA but not PsA. This may be due to delay in the diagnosis of PsA or more powerful interventions in RA. Earlier detection, lifestyle intervention, and more aggressive management strategies may be needed for PsA.
© 2020 Elsevier Inc. All rights reserved.
What is already known about this subject?
The knowledge about quality of life has so far been scarce in patients with PsA but in a recent study substantial prevalence of depression and anxiety as well as elevated incidence of depres-sion among patients with PsA were identified (Zusman EZ,How ren AM,Park JYE, et al. Semin Arthritis Rheum. 2020 Feb 13. pii: S0049-0172(20)30020-2. doi: 0.1016/j.semarthrit.2020.02.001. [Epub ahead of print].
What does this study add?
PsA and RA have similarly reduced health-related quality of life at disease onset
RA substantially improves in measures of health-related quality of life while PsA improves much slower and to a much lower extent The disease burden of PsA may be worse than previously thought
How might this impact om clinical practice?
Earlier detection, lifestyle intervention, tight disease control and more aggressive management strategies may be needed for PsA
* Corresponding author.
E-mail address:gerd-marie.alenius@umu.se(G.-M. Alenius).
https://doi.org/10.1016/j.semarthrit.2020.10.010
0049-0172/© 2020 Elsevier Inc. All rights reserved.
Contents lists available atScienceDirect
Seminars in Arthritis and Rheumatism
journal homepage:www.elsevier.com/locate/semarthritIntroduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the peripheral and axial skeleton. PsA can be a severe and erosive dis-ease with high rates of destruction in early years[1 3], with persis-tent joint inflammation associated with joint damage. PsA is associated with psoriasis (PsO), which has a reported prevalence of 2 4% in Northern Europe. Approximately 10 30% of PsO patients will develop PsA. This corresponds with the prevalence of 0.25% and 0.2% reported for PsA in southern Sweden[4]and western Norway [5]. The peak onset of PsA occurs between the age of 30 and 50 years, with an equal sex distribution[5], and, a short delay between symp-tom onset and initiation of treatment has been shown to predict a favorable clinical outcome in PsA [6,7]. Smoking[6], female sex[7], older age at onset[6], the number of swollen joints[8], elevated C-reactive protein (CRP)[9] or erythrocyte sedimentation rate (ESR) [10], and polyarthritic joint involvement[10]are some baseline vari-ables that predict an unfavorable clinical outcome. There is also an increased prevalence of subclinical atherosclerosis, obesity, arterial hypertension, and myocardial infarction[11]. Studies have had con-flicting results regarding mortality[12].
Rheumatoid arthritis (RA) affects mainly peripheral joints and, sometimes, also the cervical axial skeleton. The prevalence is approx-imately 0.5%, mainly affecting women with a sex ratio of 1:2 to 1:5 and is most prevalent in women over 65 years of age[13]. RA is also a systemic erosive disease with several co-morbidities compared with PsA.
Both PsA and RA significantly impact quality of life. Only a few reports have compared the two diseases[14 16], reporting a similar or less impact on quality of life from PsA compared with RA[16].
The aim of the current study was to evaluate the quality of life in a cohort of early PsA patients in Swedish routine care over afive-year period compared with a matched cohort of early RA patients and a matched general population.
Materials and methods
This prospective study was approved by the regional ethics com-mittee in Uppsala, Sweden. Patients with early PsA from six Swedish rheumatology clinics were enrolled for long-term follow-up between November 1999 and December 2010. The population and detailed enrollment process have been described previously [7,17,18], as well as patient inclusion and exclusion criteria[7]. Symptom duration at inclusion was at most 2 years. Data collection at inclusion and atfive years included assessment of skin and joint disease activity, biochem-ical markers, treatments, employment status, functional abilities, and health-related quality of life (HRQoL). Results from thefive-year fol-low-up on clinical outcome[7], radiographic outcome[3], treatment and prediction data[19]have been reported previously.
Early PsA was defined according to Moll and Wright[20], and later according to the ClASsification Criteria for Psoriatic Arthritis (CAS-PAR)[21]with thefirst manifestation of arthritis, enthesitis, dactyli-tis, or spondyloarthritis less than two years before thefirst visit to the rheumatology clinic. The pattern of affected joints at registry inclusion was categorized as mono- and oligoarthritis (< 5 peripheral joints; MAOA), polyarthritis ( 5 peripheral joints; PA), axial (axial only or in combination with peripheral disease), distal interphalan-geal in combination with other, and other joint patterns (including no active joint inflammation at presentation). Joint disease pattern is based on 66/68 joint count. The patients initially diagnosed according to Moll and Wright were retrospectively classified according to the CASPAR criteria[21].
Of 209 patients who completed thefive-year follow-up, 25 were excluded for incomplete Medical Outcomes Study Short Form 36 (SF-36) questionnaires, and 18 for not fulfilling the CASPAR criteria. A
total of 166 patients included in the registry between 1999 and 2007 remained in the analysis, 80 men (48%) and 86 women (52%).
Data for comparison with RA were obtained from the Swedish Early Rheumatoid Arthritis Study 2 (TIRA2) [22]. A total of 131 patients with sufficient SF-36 data at baseline or the five-year follow-up were included: 35 men (27%) and 96 women (73%). The RA patients were included in the TIRA2 registry between 2005 and 2008. Symptom duration at inclusion was at most 1 year.
Physical functional abilities were measured by the Health Assess-ment Questionnaire-Disability Index (HAQ-DI), covering eight aspects (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities) with a score from 0 to 3; lower scores indi-cating better physical function[23]. In RA, values 0.5 are consid-ered normal, an improvement of 0.22 is the minimal clinically important difference. Originally developed for RA, the index is now considered a generic tool. HAQ-DI has been shown to correlate with disability in both PsA[24]and RA[23]. HAQ-DI is a good predictor of productivity, morbidity, health care utilization, health care costs, and mortality rates[23], but has limited utility in assessing the dermato-logical effect of psoriasis.
Skin involvement and inflammation were evaluated by the Psoria-sis Area and Severity Index (PASI) with assessment of four regions of the body (head, trunk, upper limb, and lower limb) and a score of 0 to 72; a higher score indicates more severe skin disease, and PASI>10 has been suggested to be a severe disease[25].
The patients self-reported perceived pain, PsO skin disease sever-ity, and global health (patient global assessment; PGA) using 100-mm visual analog scales (VAS), with 0 indicating the least and 100 the worst perceived pain, skin disease, or PGA.
Disease activity and therapeutic efficacy were evaluated by the Disease Activity Score using 28 joints (DAS28), which was originally developed for RA patients[26]. The score has been shown to be valid for PsA, even though DAS28 excludes many joints commonly affected in PsA, such as the DIP joints of the hands. Disease Activity in Psoriatic Arthritis (DAPSA), which was specifically designed for PsA, evaluates 68 joints and correlates well with the DAS28 [19,27].
HRQoL was assessed by the SF-36[28], which has been validated for use in psoriatic arthritis and rheumatoid arthritis and for Swedish popu-lations[29]. The 36-item questionnaire assesses eight domains of life quality: physical functioning (PF), role limitations resulting from physi-cal problems (RP), bodily pain (BP), awareness of general health (GH), vitality (VT), social functioning (SF), role limitations resulting from emo-tional problems (RE), and mental health (MH). The scores from these domains can be calculated into a physical component summary (PCS) and mental component summary (MCS). The domains and component summaries in quality of life are scored from 0 (worst) to 100 (best).
SF-36 scores are dependent on age and sex. In the current study, differences from an age- and sex-adjusted general population were calculated in all domains for each patient for both baseline scores and thefive-year follow-up scores using Swedish normative SF-36 data. Therefore, values obtained for each domain consist of the baseline difference from the normative data, thefive-year difference from the normative data, and the difference in the change from the normative data. A negative difference indicates a worse HRQoL compared with the general population, and a positive difference in a change overfive years indicates an improvement compared with the normative data. Statistical analysis
All statistical calculations were performed using IBM SPSS Statis-tics for Windows version 21.063. Significance levels were set at p < 0.05. Comparisons between two groups (PsA vs. RA, or different sub-groups in each disease) were performed with independent t-tests. SF-36 scores were tested against general population values using the calculated difference in scores set against test value 0 in one-sample t-tests. Continuous variables were analyzed by linear regression.
Results
PsA and RA at baseline
At baseline, men with PsA were significantly younger, had signifi-cantly lower CRP, ESR, and HAQ-DI, and reported less pain than women (Table 1). No other significant sex differences were found. In contrast, no significant sex differences were found among the RA patients with the exception of HAQ-DI (Table 1).
Clinical comparison of the PsA and RA cohorts at baseline
Patients with PsA were significantly younger than patients with RA (Table 1), and this difference was most pronounced in men. The delay between symptom onset and inclusion in the registries was sig-nificantly shorter for RA patients. An age-adjusted analysis showed that the RA group had significantly higher DAS28 scores and swollen joint count than the PsA group, even when split by sex (Table 1). The ESR and HAQ-DI were higher in patients with RA, especially in men, whereas the tender joint count was significantly higher in women with RA. RA patients also reported higher PGA. No significant differ-ence was found in patient-perceived pain.
Comparison of SF-36 in PsA vs. RA at baseline
Both PsA and RA patients had significantly reduced HRQoL, as indicated by lower scores in all SF-36 domains and component sum-maries compared with an age-adjusted general population (p< 0.05 for all domains for both diseases;Table 2). The reduced HRQoL had similar patterns in PsA and RA, with the RE domain and MCS being the only scores significantly reduced for RA compared with PsA (RE: 24.66§43.31 (PsA) vs. 36.69§42.7 (RA), p = 0.019; MCS: -5.24§ 11.89 (PsA) vs. 8.80§11.99 (RA), p = 0.014). The impaired HRQoL was less pronounced in men with PsA than in men with RA based on the SF domain ( 12.43§21.08 (PsA) vs. 24.85§27.18 (RA), p = 0.020). In the other SF-36 domains and component scores, no sig-nificant differences were found between diseases in the deviation from the general population at baseline (Table 2).
SF-36 in PsA at thefive-year follow-up
PsA patients still had significantly impaired HRQoL compared with the general population in all SF-36 scores, by group and by sex, except for MCS in men (Table 2,Fig. 1). Overfive years, all domain and component scores for all patient subgroups had improved (Table 2,Fig 1), except for female patients in the GH domain (Table 2). However, the changes lacked significance for GH and MCS, and although the SF score significantly improved (p = 0.013), the change did not reach significance for either sex. Furthermore, females lacked a significant improvement in the RE domain (Table 2).
Linear regression analysis of PCS and MCS in PsA
In a univariate age-adjusted linear regression analysis, DAS28, HAQ, and PGA at baseline negatively correlated with PCS at the five-year follow-up (p = 0.006, p< 0.001, and p < 0.001, respectively; Table 3). In a multivariate analysis with delay of specialist care, DAS28, HAQ-DI, PGA, and age, there was an independent negative correlation between delay, HAQ-DI, and PGA (p = 0.038, p = 0.004, and p = 0.030, respectively) and PCS (Table 3). DAS28, HAQ-DI, and PGA negatively correlated with MCS at thefive-year follow-up in a univariate analysis (p = 0.004, p< 0.001, and p = 0.001, respectively). In a multivariate analysis, only PGA independently correlated with MCS (p = 0.031;Table 3). Table 1 Baseline characteristics of PsA and RA patients, including age-adjusted differences of baseline characteristics between PsA and RA. PsA patients RA patients All (n = 166) Men (n = 80) Women (n = 86) All (n = 131) Men (n = 35) Women (n = 96) p -values for age adjusted differences PsA vs. RA Mean (§ SD) Mean (§ SD) Mean (§ SD) p -value men vs. women Mean (§ SD) Mean (§ SD) Mean (§ SD) p -value men vs. women All Men Women Age 45.9 (14.8) 42.9 (13.7) 48.6 (15.3) 0.013 57.7 (12.6) 59.9 (11.3) 56.9 (13.1) 0.225 < 0.001 < 0.001 < 0.001 Delay (months) 11.2 (6.4) 12 (6.6) 10.5 (6.1) 0.143 6.6 (6.1) 5.9 (3.7) 6.9 (76.7) 0.402 < 0.001 < 0.001 0.001 CRP 16.1 (27.6) 11.2 (9.2) 20.6 (36.7) 0.024 ESR 17 (18) 13 (12) 21 (22) 0.004 31 (23) 35 (28) 30 (21) 0.248 0.001 < 0.001 0.147 DAS28 3.32 (1.35) 3.1 (1.2) 3.49 (1.42) 0.060 4.98 (1.36) 4.91 (1.40) 5.01 (1.35) 0.727 < 0.001 < 0.001 < 0.001 DAPSA 19.1 (13.9) 17 (11.6) 20.9 (15.5) 0.102 HAQ-DI 0.59 (0.53) 0.43 (0.39) 0.72 (0.61) < 0.000 0.85 (0.58) 0.64 (0.53) 0.92 (0.58) 0.027 0.011 0.011 0.279 PASI 3.0 (3.7) 3.4 (4.1) 2.5 (3.1) 0.116 PGA VAS 40 (26) 37 (24) 43 (26) 0.207 50 (24) 46 (27) 51 (23) 0.322 0.017 0.108 0.110 PsO VAS 27 (26) 28 (25) 26 (27) 0.611 Pain VAS 41 (26) 37 (25) 45 (26) 0.042 48 (26) 40 (26) 50 (25) 0.050 0.055 0.199 0.286 Tender joints 5 (6.1) 5 (6.1= 4.9 (6.1) 0.952 7.6 (6.2) 6.4 (6.0) 8.0 (6.3) 0.184 0.009 0.668 0.007 Swollen joints 4.3 (4.8) 4 (4.1) 4.3 (5.4) 0.688 8. (5.7) 9.5 (6.5) 7.5 (5.4) 0.071 < 0.001 < 0.001 0.002 n (%) n (%) n (%) p -value men vs. women Polyarthritis 76 (45.8) 34 (42.5) 42 (49) 0.439 Mono-/oligoarthritis 77 (46.4) 41 (51.2) 36 (42) 0.276 Axial joint pattern 16 (9.6) 8 (10) 8 (9.3) 0.679 Independent samples t-test between males and females for continuous variables. Pearson Chi-square test between males and females for nominal variables (joint patterns) .Overlapping joint pattern in 12 PsA patients: 8 axial+PA, 4 axial +MAOA. CRP; C-reactive protein, DAPSA; Disease Activity in Psoriatic Arthritis, DAS28; Disease Activity Score using 28 joints, ESR; Erythrocyte se dimentation rate, HAQ-DI; Health Assessment Questionnaire-Disability Index, MAOA; Mono-/oligoarthritis, PA; Polyarthritis, PASI; Psoriasis Area and Severity Index, PGA; Patient reported global health assessment, PsO; Psoriasi s, VAS; Visual analog scale.
The importance of PsA joint patterns for HRQoL in PsA
Only PA and MAOA joint patterns were of large enough sample size to yield statistical power. In an analysis between the two, both for the whole groups and by sex, PA patients had more impaired HRQoL in most SF-36 domains at both inclusion andfive years. PA patients also had a less favorable change overfive years than MAOA patients in most SF-36 subscales. However, these differences only reached significance in GH (men; p = 0.036) and VT (all and men; p = 0.020 and 0.005) at baseline and in VT (all and women; p = 0.019 and 0.041), SF (all; p = 0.014), MH (all and women; p = 0.014 and 0.011), and MCS (all and women; p = 0.003 and 0.12) at thefive-year follow-up (Data not shown).
SF-36 in RA at thefive-year follow-up
RA patients as a group differed significantly from the general pop-ulation in all scores except SF, RE, MH, and MCS at thefive-year fol-low-up (Table 2, Figure). When split by sex, men with RA did not differ significantly from the general population in any domain or component summary. In contrast, women differed significantly in all domains except RP, SF, RE, MH, and MCS. Overfive years, an improve-ment was seen in all domains and component scores for all patient groups (Table 2, Figure). This was significant in all domains and com-ponent scores except for men in the GH domain.
Comparison of SF-36 in PsA and RA at thefive-year follow-up
Atfive years, PsA patients had improved considerably less than RA patients (Table 2, Figure). PsA patients had significantly lower scores than RA patients in all SF-36 domains except RE, MH, and MCS, and women also had a significant difference in the RE domain. However, men only differed significantly in the BP domain (p = 0.029). No trend
toward normalization of HRQoL atfive years was shown in the PsA group, but a trend was shown for the RA group. PsA patients had less improvement than RA patients in the absolute values for all domains and component summaries both as whole groups and when ana-lyzed by sex. The differences between the diseases in change over five years were significant in all domains and component summaries when compared by whole groups. When analyzed by sex, changes for men were significant only for BP and SF (p = 0.001 and p < 0.001, respectively). For women, the significance remained for all domains and component summaries except for the SF domain.
Discussion
In the current study, HRQoL in early PsA at baseline and afterfive years was compared with an early RA cohort and an age- and sex-adjusted general population. Both PsA and RA patients presented with a significant reduction in HRQoL in all SF-36 domains and com-ponent scores compared with an age- and sex-adjusted general Swedish population, without sex differences. After five years, PsA patients, but not RA patients, still had significantly reduced HRQoL in all SF-36 scores, even though they had improved significantly in HRQoL.
Similar to the results from the current study, impaired HRQoL in early PsA and early RA was reported previously[16]when compari-sons were made between early PsA and early RA, as well as a general population, regarding HRQoL at baseline and after two years of treat-ment with etanercept. In that study, only absolute SF-36 scores were used without adjusting for age or sex, making direct comparisons impossible. In another study[30], evaluating the effect of Etanercept treatment, RA and PsA showed similarly reduced SF-36 scores at inclusion, more pronouncedly poor for RA. At the study endpoint, at 52 weeks’ treatment with etanercept and methotrexate for RA and 24 weeks’ treatment with etanercept for PsA, both diseases had
Table 2
Difference in SF-36 scores from a general population with significance levels versus general population, and between diseases.
All Men Women
PsA p RA p diff. PsA/RA PsA p RA p p diff. PsA/RA PsA p RA p p diff. PsA/RA PF baseline 24.30 < 0.001 22.50 < 0.001 0.520 25.67 < 0.001 23.35 < 0.001 0.652 23.03 < 0.001 22.22 < 0.001 0.816 5-year 13.93 < 0.001 4.75 0.005 0.001 10.97 < 0.001 1.91 0.577 0.059 16.67 < 0.001 5.81 0.014 0.002 change 10.27 < 0.001 17.35 < 0.001 0.031 14.52 < 0.001 19.92 < 0.001 0.415 6.36 0.015 16.50 < 0.001 0.008 RP baseline 46.64 < 0.001 48.13 < 0.001 0.742 48.03 < 0.001 49.12 < 0.001 0.901 45.35 < 0.001 47.82 < 0.001 0.664 5-year 21.15 < 0.001 7.89 0.033 0.008 17.81 < 0.001 11.17 0.127 0.428 24.27 < 0.001 6.69 0.120 0.007 change 24.99 < 0.001 38.83 < 0.001 0.030 29.87 < 0.001 33.48 0.005 0.805 20.45 0.001 40.51 < 0.001 0.010 BP baseline 32.27 < 0.001 34.63 < 0.001 0.373 32.19 < 0.001 37.91 < 0.001 0.229 32.35 < 0.001 33.42 < 0.001 0.745 5-year 17.36 < 0.001 5.63 0.009 < 0.001 15.86 < 0.001 4.87 0.220 0.029 18.76 < 0.001 5.89 0.023 0.001 change 14.91 < 0.001 29.13 < 0.001 < 0.001 16.33 < 0.001 33.78 < 0.001 0.001 13.59 < 0.001 27.44 < 0.001 < 0.001 GH baseline 17.91 < 0.001 14.56 < 0.001 0.165 19.02 < 0.001 15.53 < 0.001 0.410 16.88 < 0.001 14.23 < 0.001 0.372 5-year 16.40 < 0.001 5.72 0.004 < 0.001 15.29 < 0.001 8.17 0.057 0.167 17.42 < 0.001 4.89 0.029 < 0.001 change 1.26 0.409 8.71 < 0.001 0.001 3.24 0.149 6.84 0.120 0.311 0.54 0.796 9.28 < 0.001 0.001 VT baseline 23.12 < 0.001 26.84 < 0.001 0.165 23.12 < 0.001 15.53 < 0.001 0.289 23.11 < 0.001 26.25 < 0.001 0.328 5-year 13.36 < 0.001 6.20 0.002 0.011 10.98 < 0.001 6.85 0.089 0.428 15.58 < 0.001 5.96 0.011 0.006 change 9.75 < 0.001 19.54 < 0.001 0.001 12.15 < 0.001 19.92 0.001 0.151 7.53 0.008 19.42 < 0.001 0.001 SF baseline 15.39 < 0.001 19.08 < 0.001 0.222 12.43 < 0.001 24.85 < 0.001 0.020 18.15 < 0.001 16.97 < 0.001 0.771 5-year 9.68 < 0.001 1.57 0.393 0.003 7.78 0.009 0.11 0.971 0.069 11.44 < 0.001 2.10 0.355 0.011 change 5.71 0.013 17.17 < 0.001 0.001 4.65 0.121 24.89 < 0.001 < 0.001 6.70 0.056 14.41 < 0.001 0.084 RE baseline 24.66 < 0.001 36.69 < 0.001 0.019 25.19 < 0.001 38.01 < 0.001 0.147 24.16 < 0.001 36.21 < 0.001 0.067 5-year 15.62 < 0.001 6.41 0.054 0.050 9.69 0.031 6.33 0.308 0.667 21.06 < 0.001 6.44 0.106 0.021 change 9.55 0.021 29.95 < 0.001 0.001 17.19 0.001 31.94 0.002 0.107 2.63 0.680 29.21 < 0.001 0.001 MH baseline 12.28 < 0.001 15.55 < 0.001 0.144 12.97 < 0.001 14.87 < 0.001 0.656 11.63 < 0.001 15.76 < 0.001 0.133 5-year 5.33 0.001 2.40 0.125 0.194 5.35 0.034 1.08 0.660 0.221 5.31 0.014 2.90 0.139 0.403 change 6.95 < 0.001 12.82 < 0.001 0.014 7.62 0.001 14.11 0.001 0.120 6.33 0.007 12.41 < 0.001 0.048 PCS baseline 13.48 < 0.001 11.72 < 0.001 0.135 13.86 < 0.001 11.77 < 0.001 0.381 13.14 < 0.001 11.70 < 0.001 0.331 5-year 7.89 < 0.001 2.67 0.006 < 0.001 7.08 < 0.001 3.06 0.098 0.091 8.62 < 0.001 2.54 0.026 < 0.001 change 5.74 < 0.001 9.15 < 0.001 0.014 7.23 < 0.001 8.63 0.004 0.607 4.44 < 0.001 9.29 < 0.001 0.004 MCS baseline 5.24 < 0.001 8.80 < 0.001 0.014 4.70 0.001 9.99 < 0.001 0.050 5.73 < 0.001 8.45 < 0.001 0.133 5-year 3.03 0.003 1.13 0.217 0.162 2.12 0.150 1.46 0.287 0.739 3.84 0.007 1.01 0.376 0.118 change 2.21 0.050 7.00 < 0.001 0.004 2.74 0.056 8.29 0.012 0.073 1.75 0.306 6.66 < 0.001 0.021 One-sample t-test vs. value 0 (general population) for baseline values, 5-year values and difference from normal change. Independent samples t-test for differences between PsA and RA.
improved but RA still showed worse SF-36 scores than PsA in contrast to the current study.
In our study, the inferior HRQoL for both diseases lacked sex dif-ferences, in contrast to a previous study of HRQoL in early RA that reported better scores in PF, BP, and SF at inclusion for women com-pared with men [31], though with a reduced difference after six years. Another study on early RA reported improvement over three years in all domains except VT and GH[32]. Lower PCS and MCS in PsA compared with a general population were reported previously [33 35]. The current results indicate that both RA and PsA have a catch-up effect in HRQoL when under rheumatological specialist care, but that RA patients improve significantly more than PsA patients. However, previous studies using other outcome measures have not shown the same difference between PsA and RA. One study using the generic HRQoL tool EuroQol-5D as an outcome measure
found no significant differences in HRQoL between PsA and RA in established disease with 10-year duration[15]. Another comparative study with a mean disease duration of 14.2 (PsA) and 12.6 years (RA) reported more role limitations in PsA patients due to emotional prob-lems and bodily pain than in RA patients; however, RA patients reported lower vitality[14].
A longer time between onset of disease andfirst-time assessment by a rheumatological specialist correlated with lower HRQoL expressed as a lower PCS score atfive years. This is in line with previ-ousfindings indicating that shorter symptom duration predicts a bet-ter clinical outcome[7]. The RA patients had a shorter initial delay and better outcome afterfive years regarding HRQoL, possibly due to more intensive intervention on the high disease burden at onset. The two cohorts in the current study were initiated during slightly differ-ent time periods: the PsA cohort between November 1999 and
Fig. 1. Spider plots showing the differences in SF-36 scores from an age- and sex-matched general population compared with the PsA and RA populations at baseline and at the five-year follow-up. There were similar poor SF-36 scores at baseline, slightly worse for RA compared with PsA, and nearly normalized SF-36 scores in all domains for RA after 5 five-years but only moderate improvement for PsA.
BP; bodily pain, GH; perception of general health, MCS; mental component summary, MH; mental health, PCS; physical component summary, PF; physical functioning, RE; role limitations resulting from emotional problems, RP; role limitations resulting from physical problems, SF; social functioning, VT; vitality.
Table 3
Linear regression analysis of variables’ effect on PCS and MCS in PsA patients at the 5-year follow-up.
PCS 5 year univariate age adjusted PCS 5 year multivariate MCS 5 year univariate age adjusted MCS 5 year multivariate B (SE) R2 adj. n p B (SE) R2 adj. N p B (SE) R2 adj. p B (SE) R2 adj. p Delay (months) 0.214 (0.137) 0.009 157 0.120 0.277 (0.132) 0.161 138 0.038 0.062 (0.156) 0.012 0.693 0.083 (0.157) 0.098 0.597 DAS28 1.932 (0.690) 0.047 139 0.006 0.801 (0.892) 0.371 2.330 (0.795) 0.046 0.004 0.351 (1.064) 0.742 HAQ-DI 7.959 (1.542) 0.139 161 < 0.001 5.996 (2.037) 0.004 6.800 (1.886) 0.068 < 0.001 4.629 (2.430) 0.059 PGA 0.132 (0.033) 0.087 158 < 0.001 0.099 (0.045) 0.030 0.136 (0.039) 0.064 0.001 0.117 (0.054) 0.031 Age 0.060 (0.060) < 0.001 161 0.313 0.910 (0.062) 0.140 0.052 (0.070) 0.003 0.457 0.035 (0.073) 0.636 DAS28; Disease Activity Score using 28 joints, HAQ-DI; Health Assessment Questionnaire-Disability Index, MCS; Mental component summary, PCS; Physical component summary, PGA; Patient reported global health assessment.
December 2010, with most patients recruited during thefirst half of that decade, and the RA cohort between 2005 and 2008. Thus, the first anti-TNF treatment was available for early RA, but not for early PsA, which may have influenced the outcome. Although both diseases have a significantly reduced HRQoL compared with a general popula-tion at onset, the slow but substantial radiographic changes in PsA, compared with the often more rapid and dramatic changes in RA, may also influence treatment intensity. In an analysis of 72 patients with full sets of hand and foot radiographs in the SwePsA cohort[3], only eight had a score> 10 using the Wassenberg[36]scoring sys-tem. In a previous analysis of treatment in the SwePsA cohort, 23 of 198 patients were treated with TNF-inhibitors at thefive-year fol-low-up, but none at inclusion[19].
The PsA and RA cohorts were followed without predefined treat-ment regimens, but the RA-patients had a more structured follow-up compared to the PsA-patients. This observational setting results is the main limitation of the current study, not allowing for taking treat-ment of PsA and RA into consideration when comparing longitudinal changes in HRQoL. The discrepancies between RA and PsA at the five-year follow-up may have been due to more aggressive intervention provoked by the disease severity in RA.
The patient sample size was too small to draw any conclusions regarding how different joint patterns affect HRQoL or to evaluate axial disease.
There are limitations to our study. One of the limitations is the measurement of activity, where we used DAS28. DAS28 does not account for all the joints that may be involved in PsA and may not accurately reflect disease activity, especially in patients with MOAO. Anyhow, DAS28 does correlate to DAPSA and since DAS28 is used in the measurement of RA disease activity, it was possible for us to compare patients with PsA and RA which was the main object in this study
We did not have any patients with psoriasis without arthritic dis-ease, which is another limitation. Furthermore, we did not analyze psoriasis as a specific entity in the PsA group since it is difficult to separate the two disease manifestations in a PsA cohort and its impact on HRQoL. It would be of great interest to compare psoriatic populations, with and without arthritis in a future study. In this study we wanted to compare the two rheumatic diseases, PsA and RA, which is of clinical interest in a rheumatic context.
In conclusion, the current study showed that patients with early PsA and early RA had an almost equally low HRQoL at disease onset compared with an age- and sex-adjusted general population. After five years, RA patients exhibited significant improvement, almost normalizing their HRQoL. In patients with PsA, an improvement was seen in most SF-36 scores, but they still had significantly lower HRQoL than a general population with lower scores in all SF-36 domains except MCS for men. The reasons for the persistently impaired HRQoL in PsA are unclear. Aggressive intervention pro-voked by the disease severity in RA and a long delay from symptom onset until rheumatological care, high disability, and PGA scores at disease onset had independent negative effects on HRQoL afterfive years of disease. Earlier detection and more aggressive lifestyle and medical interventions may prevent long-term low HRQoL.
Contributorship
Study design: GA, TH, PL, UL, ET. Acquisition of data: GA, TH, PL, UL, IT, ET. Statistical analysis and interpretation of data. LA, ET. Manu-script: MG, GA, LA, TH, PL, UL, IT, ET,
Funding
The work was funded by grants from The Swedish Psoriasis Foun-dation.
Ethical improvement
The project was approved by The Regional Ethics Committee of Uppsala University, Sweden. Participants have given the informed consent before participating in the study.
Declaration of Competing Interest
In addition to academic research at Lund University, ET has been employee of Janssen Cilag since 2015. MG has received consultancy fees from AbbVie, Novartis and Pfizer (unrelated to the present work). There are no other conflict interests.
Acknowledgment
We acknowledge Bj€orn Svensson for initiating the SwePsA, Gunilla Holmstr€om and Annika Teleman for fruitful cooperation and support for the SwePsA, and Mikael Ek, patient representative, for valuable cooperation.
References
[1]Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and
radiologi-cal study of early psoriatic arthritis: an early synovitis clinic experience. Rheuma-tology (Oxford) 2003;42:1460–8.
[2]McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in
pso-riatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778–83.
[3]Geijer M, Lindqvist U, Husmark T, Alenius G-M, Larsson PT, Teleman A, et al. The
Swedish early psoriatic arthritis registry 5-year follow-up: substantial radio-graphic progression mainly in men with high disease activity and development of dactylitis. J Rheumatol 2015;42:2110–7.
[4]Haglund E, Bremander AB, Petersson IF, Strombeck B, Bergman S, Jacobsson LT,
et al. Prevalence of spondyloarthritis and its subtypes in Southern Sweden. Ann Rheum Dis 2011;70:943–8.
[5]Madland TM, Apalset EM, Johannessen AE, Rosseb€o B, Brun JG. Prevalence, disease
manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheu-matol 2005;32:1918–22.
[6]Tillett W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, et al.
Smok-ing and delay to diagnosis are associated with poorer functional outcome in pso-riatic arthritis. Ann Rheum Dis 2013;72:1358–61.
[7]Theander E, Husmark T, Alenius G-M, Larsson PT, Teleman A, Geijer M, et al. Early
psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePsA). Ann Rheum Dis 2014;73:407–13.
[8]Simon P, Pfoehler C, Bergner R, Schreiber M, Pfreundschuh M, Assmann G.
Swol-len joint count in psoriatic arthritis is associated with progressive radiological damage in hands and feet. Clin Exp Rheumatol 2012;30:45–50.
[9]Gladman DD, Mease PJ, Choy EHS, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for
radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. Arthritis Res Ther 2010;12:R113.
[10]Coates LC, Cook R, Lee K-A, Chandran V, Gladman DD. Frequency, predictors, and
prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010;62:970–6.
[11]Coates LC, FitzGerald O, Helliwell PS, Paul C. Psoriasis, psoriatic arthritis, and
rheuma-toid arthritis: is all inflammation the same? Semin Arthritis Rheum 2016;46:291–304.
[12]Juneblad K, Rantap€a€a-Dahlqvist S, Alenius G-M. Disease activity and increased
risk of cardiovascular death among patients with psoriatic arthritis. J Rheumatol 2016;43:2155–61.
[13]Simonsson M, Bergman S, Jacobsson LT, Petersson IF, Svensson B. The prevalence
of rheumatoid arthritis in Sweden. Scand J Rheumatol 1999;28:340–3.
[14]Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of
patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151–8.
[15]Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid
and psoriatic arthritis. J Rheumatol 2001;28:1842–6.
[16]Picchianti-Diamanti A, Germano V, Ferlito C, Migliore A, D’Amelio R, Lagana B.
Health-related quality of life and disability in patients with rheumatoid, early rheu-matoid and early psoriatic arthritis treated with etanercept. Qual Life Res 2010;19:821–6.
[17]Svensson B, Holmstr€om G, Lindqvist U. Development and early experiences of a
Swedish psoriatic arthritis register. Scand J Rheumatol 2002;31:221–5.
[18]Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstr€om G, Larsson PT. The
Swedish early psoriatic arthritis register 2-year followup: a comparison with
early rheumatoid arthritis. J Rheumatol 2008;35:668–73.
[19]Lindqvist U, Wernroth M-L, Husmark T, Larsson PP, Geijer M, Teleman A, et al.
DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish early psoriatic arthritis cohort. Clin Exp Rheumatol 2017;35:936–42.
[21]Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classifica-tion criteria for psoriatic arthritis: development of new criteria from a large inter-national study. Arthritis Rheum 2006;54:2665–73.
[22]Thyberg I, Dahlstr€om €O, Bj€ork M, Stenstr€om B, Adams J. Hand pains in women and
men in early rheumatoid arthritis, a one year follow-up after diagnosis. The Swedish TIRA project. Disabil Rehabil 2016:1–10.
[23]Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its
history, issues, progress, and documentation. J Rheumatol 2003;30:167–78.
[24]Mease PJ. Assessing the impact of psoriatic arthritis on patient function and
qual-ity of life: lessons learned from other rheumatologic conditions. Semin Arthritis Rheum 2009;38:320–35.
[25]Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152
(5):861–7.
[26]Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel
PL. Modified disease activity scores that include twenty-eight-joint counts. Devel-opment and validation in a prospective longitudinal study of patients with rheu-matoid arthritis. Arthritis Rheum 1995;38:44–8.
[27] Mease PJ. Measures of psoriatic arthritis: tender and swollen joint
assess-ment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcas-tle enthesitis index (MEI), leeds enthesit. Arthritis Care Res (Hoboken) 2011;63:S64–85.
[28]Ware Jr JE. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
Conceptual framework and item selection. Med Care 1992;30:473–83.
[29]Persson LO, Karlsson J, Bengtsson C, Steen B, Sullivan M. The Swedish SF-36 health
survey II. Evaluation of clinical validity: results from population studies of elderly and women in Gothenborg. J Clin Epidemiol 1998;51:1095–103.
[30]Strand V, Sharp V, Koenig A, Park G, Shi Y, Wang B, et al. Comparison of
health-related quality of life in rheumatoid arthritis, psoriatic arthritis, and psoriasis and effects of etanercept treatment. Ann Rheum Ds 2012;71:1143–50.
[31]West E, Wa
llberg-Jonsson S. Health-related quality of life in Swedish men and women with early rheumatoid arthritis. Gend Med 2009;6:544–54.
[32]da Mota LMH, Laurindo IMM, dos Santos Neto LL. Prospective evaluation of the
quality of life in a cohort of patients with early rheumatoid arthritis. Rev Bras Reumatol 2010;50:249–61.
[33]Kavanaugh A, Antoni C, Krueger GG, Yan S, Bala M, Dooley LT, et al. Infliximab
improves health related quality of life and physical function in patients with pso-riatic arthritis. Ann Rheum Dis 2006;65:471–7.
[34]Kavanaugh A, McInnes IB, Krueger GG, Gladman D, Beutler A, Gathany T, et al.
Patient-reported outcomes and the association with clinical response in patients
with active psoriatic arthritis treated with golimumab:findings through 2 years
of a phase III, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Care Res (Hoboken) 2013;65:1666–73.
[35]Tsuji S, Higashiyama M, Inaoka M, Tomita T, Yokomi A, Satoh A, et al. Effects of
adali-mumab therapy on musculoskeletal manifestations and health-related quality of life in patients with active psoriatic arthritis. Mod Rheumatol 2013;23:529–37.
[36]Wassenberg S, Fischer-Kahle V, Herborn G, Rau R. A method to score radiographic
